# Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy

> **NCT07022743** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Obafemi Awolowo University** · enrollment: 75 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia (CML)

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Artesunate

## Key facts

- **NCT ID:** NCT07022743
- **Lead sponsor:** Obafemi Awolowo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07022743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07022743, "Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07022743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*